Skip to main content

Phase II evaluation of iproplatin in patients with advanced gastric and pancreatic cancer.

Publication ,  Journal Article
Hubbard, KP; Pazdur, R; Ajani, JA; Braud, E; Blaustein, A; King, M; Llenado-Lee, M; Winn, R; Levin, B; Abbruzzese, JL
Published in: Am J Clin Oncol
December 1992

A total of 48 patients with measurable advanced gastric adenocarcinoma (n = 16) or adenocarcinoma of the exocrine pancreas (n = 32) were prospectively treated with iproplatin at a starting dose of 270 mg/m2 intravenously over 2 hours. The dose was repeated every 28 days, and dose escalations or reductions were made on the basis of toxicity in the preceding course. No patient with gastric carcinoma achieved either a complete or partial response. One partial response and two complete responses were seen with pancreatic adenocarcinoma for an overall response rate of 10%. One patient has remained free of disease for more than 2 years. The major toxicities were granulocytopenia, thrombocytopenia, nausea, vomiting, and diarrhea. All toxicities were reversible upon discontinuation of the drug. On the basis of this trial, we conclude that iproplatin has no substantive activity in advanced gastric or pancreatic carcinomas.

Duke Scholars

Published In

Am J Clin Oncol

ISSN

0277-3732

Publication Date

December 1992

Volume

15

Issue

6

Start / End Page

524 / 527

Location

United States

Related Subject Headings

  • Stomach Neoplasms
  • Prospective Studies
  • Pancreatic Neoplasms
  • Organoplatinum Compounds
  • Oncology & Carcinogenesis
  • Middle Aged
  • Male
  • Humans
  • Female
  • Antineoplastic Agents
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Hubbard, K. P., Pazdur, R., Ajani, J. A., Braud, E., Blaustein, A., King, M., … Abbruzzese, J. L. (1992). Phase II evaluation of iproplatin in patients with advanced gastric and pancreatic cancer. Am J Clin Oncol, 15(6), 524–527.
Hubbard, K. P., R. Pazdur, J. A. Ajani, E. Braud, A. Blaustein, M. King, M. Llenado-Lee, R. Winn, B. Levin, and J. L. Abbruzzese. “Phase II evaluation of iproplatin in patients with advanced gastric and pancreatic cancer.Am J Clin Oncol 15, no. 6 (December 1992): 524–27.
Hubbard KP, Pazdur R, Ajani JA, Braud E, Blaustein A, King M, et al. Phase II evaluation of iproplatin in patients with advanced gastric and pancreatic cancer. Am J Clin Oncol. 1992 Dec;15(6):524–7.
Hubbard, K. P., et al. “Phase II evaluation of iproplatin in patients with advanced gastric and pancreatic cancer.Am J Clin Oncol, vol. 15, no. 6, Dec. 1992, pp. 524–27.
Hubbard KP, Pazdur R, Ajani JA, Braud E, Blaustein A, King M, Llenado-Lee M, Winn R, Levin B, Abbruzzese JL. Phase II evaluation of iproplatin in patients with advanced gastric and pancreatic cancer. Am J Clin Oncol. 1992 Dec;15(6):524–527.

Published In

Am J Clin Oncol

ISSN

0277-3732

Publication Date

December 1992

Volume

15

Issue

6

Start / End Page

524 / 527

Location

United States

Related Subject Headings

  • Stomach Neoplasms
  • Prospective Studies
  • Pancreatic Neoplasms
  • Organoplatinum Compounds
  • Oncology & Carcinogenesis
  • Middle Aged
  • Male
  • Humans
  • Female
  • Antineoplastic Agents